In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

“ATR-258, a synthetic small molecule, has favourable pharmacokinetics and in Phase 1 clinical trials has been administered just once a day as a capsule, making it a straightforward, patient-friendly ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm ...

When it comes to drug development, for example, there's a lot more risk associated with developing so called first in class drugs compared to simply making small tweaks over the same kind of old drug.

ProteinQure’s lead candidate, PQ203, is a first-in-class peptide-drug conjugate designed to target the sortilin receptor, which is overexpressed in many solid tumors, including TNBC.

StarMab BioMed’s First-in-Class, Dual-Target Anti-Tumor Drug SM2275 for Novel Immunotherapy Receives FDA IND Approval. News provided by. EIN Presswire Apr 07, 2025, 4:43 AM ...